Drug Profile
Glycopyrrolate/indacaterol - Novartis
Alternative Names: Indacaterol maleate/glycopyrronium bromide; Indacaterol/glycopyrrolate; Indacaterol/NVA-237; NVA-237/indacaterol; NVA-237/QAB-149; QVA-149; Ultibro Breezhaler; Ultibro Inhalation Capsules; UltibroBreezhaler; Ulunar Breezhaler; Utibron Neohaler; Xoterna BreezhalerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Arakis Ltd; Novartis; Vectura
- Developer Novartis; Pfizer; Sumitomo Pharma America
- Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 05 Jan 2022 Covis Pharmaceuticals entered into a Distribution Agreement with Novartis Pharmaceuticals Canada
- 06 Oct 2021 Orion completes the phase I FINDA trial in Chronic obstructive pulmonary disease (In volunteers) in Finland (Inhalation) (NCT04856098)
- 07 May 2021 Orion initiates the phase I FINDA trial (In volunteers) in Finland (Inhalation) (NCT04856098)